Form 4: Madrigal Director Exercises Options, Sells Shares

Madrigal Pharmaceuticals Director Paul A. Friedman exercised stock options and subsequently sold a corresponding number of common shares under a pre-arranged 10b5-1 trading plan.

Summary

• Paul A. Friedman, a Director of Madrigal Pharmaceuticals, Inc. (MDGL), engaged in transactions involving the company's common stock.
• Exercised 24,520 stock options at an exercise price of $15.80 per share on January 9, 2026.
• Immediately after the exercise, sold 24,520 shares of common stock in multiple transactions on January 9, 2026.
• The sales were executed at weighted average prices ranging from $511.98 to $540.36 per share.
• These transactions were conducted under a Rule 10b5-1 trading plan established on September 10, 2025.
• Following these transactions, direct beneficial ownership decreased to 187,164 shares.
• Indirect beneficial ownership through SQN LLC remains at 655,540 shares, with the reporting person disclaiming beneficial ownership except to the extent of pecuniary interest.
• 280 stock options remain beneficially owned, which are fully vested and exercisable with an expiration date of March 2, 2027.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a pre-planned insider sale, which is common for executives managing their equity compensation. It is not inherently positive or negative for the company's operational performance or future prospects, but simply a director monetizing vested options.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned sales rather than reactive market timing, which can reduce concerns about insider sentiment.
• The exercise price of the options ($15.80) is significantly lower than the sale prices (ranging from $511.98 to $540.36), indicating a substantial gain for the director from vested equity.

Negatives

• A director selling a significant number of shares, even if pre-planned, could be perceived negatively by some investors as it reduces insider holdings.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports an insider transaction for Madrigal Pharmaceuticals, a company operating in the biotechnology and pharmaceutical sector. Such transactions are routine for executives managing their equity compensation and are not typically indicative of broader industry trends, though they provide transparency into insider holdings.

Related Party Transactions

• The reporting person and his spouse are each managing members of SQN, LLC, which indirectly owns 655,540 shares. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Stakeholder Impact

• Shareholders: May observe a director monetizing equity, which is a routine part of executive compensation but can sometimes be viewed with caution if not understood as pre-planned and for personal financial management.

Key Dates

Recommendation

The filing details a pre-planned insider transaction (option exercise and sale) by a director. Such transactions, especially when executed under a Rule 10b5-1 plan, are typically for personal financial planning and do not necessarily reflect a change in the director's outlook on the company's fundamentals. Therefore, this specific filing alone does not warrant a change in investment recommendation; a 'hold' stance is maintained pending further operational or strategic updates from Madrigal Pharmaceuticals.

Keywords

Madrigal Pharmaceuticals, MDGL, Paul A. Friedman, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Director Transaction, Biotechnology, Pharmaceuticals